- Home
- REBN vs NXTC Comparison
REBN vs NXTC Comparison
Compare REBN & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REBN
- NXTC
- Stock Information
- Founded
- REBN 2015
- NXTC 2015
- Country
- REBN United States
- NXTC United States
- Employees
- REBN N/A
- NXTC N/A
- Industry
- REBN Restaurants
- NXTC Biotechnology: Pharmaceutical Preparations
- Sector
- REBN Consumer Discretionary
- NXTC Health Care
- Exchange
- REBN Nasdaq
- NXTC Nasdaq
- Market Cap
- REBN 15.3M
- NXTC 13.0M
- IPO Year
- REBN 2022
- NXTC 2019
- Fundamental
- Price
- REBN $2.42
- NXTC N/A
- Analyst Decision
- REBN
- NXTC Strong Buy
- Analyst Count
- REBN 0
- NXTC 2
- Target Price
- REBN N/A
- NXTC $25.50
- AVG Volume (30 Days)
- REBN 77.7K
- NXTC 10.5K
- Earning Date
- REBN 11-18-2025
- NXTC 11-06-2025
- Dividend Yield
- REBN N/A
- NXTC N/A
- EPS Growth
- REBN N/A
- NXTC N/A
- EPS
- REBN N/A
- NXTC N/A
- Revenue
- REBN $6,565,623.00
- NXTC N/A
- Revenue This Year
- REBN $335.98
- NXTC N/A
- Revenue Next Year
- REBN N/A
- NXTC N/A
- P/E Ratio
- REBN N/A
- NXTC N/A
- Revenue Growth
- REBN 14.03
- NXTC N/A
- 52 Week Low
- REBN $1.03
- NXTC $2.69
- 52 Week High
- REBN $8.30
- NXTC $19.20
- Technical
- Relative Strength Index (RSI)
- REBN N/A
- NXTC N/A
- Support Level
- REBN N/A
- NXTC N/A
- Resistance Level
- REBN N/A
- NXTC N/A
- Average True Range (ATR)
- REBN 0.00
- NXTC 0.00
- MACD
- REBN 0.00
- NXTC 0.00
- Stochastic Oscillator
- REBN 0.00
- NXTC 0.00
About REBN Reborn Coffee Inc.
Reborn Coffee Inc is an operator and franchisor of retail locations and kiosks that focus on serving specialty-roasted coffee. It is an company that strives for constant improvement in the coffee experience through exploration of new technology and premier service, guided by traditional brewing techniques. The company operates in one reportable segment, consisting of both the wholesale and retail sales of coffee, water, and other beverages.
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.